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Abstract 
Zinc-2-glycoprotein (ZAG) is a new adipokine with the potential to treat obesity.  In 
this study, mature male Wistar rats (540±83g) were administered human recombinant 
ZAG, (50g/100g body weight given i.v. daily) for 10 days, while control animals 
received an equal volume of PBS.  Animals treated with ZAG showed a progressive 
decrease in body weight, without a decrease in food and water intake, but with a 
0.4°C rise in body temperature.  Body composition analysis showed loss of adipose 
tissue, but an increase in lean body mass.  The loss of fat was due to an increase in 
lipolysis as shown by a 50% elevation of plasma glycerol, together with increased 
utilisation, as evidenced by the 55% decrease in plasma levels of non-esterified fatty 
acids.  Plasma levels of glucose and triglycerides were also reduced by 36-37% and 
there was increased expression of glucose transporter 4 in both skeletal muscle and 
adipose tissue.  Expression of the lipolytic enzymes adipose triglyceride lipase and 
hormone sensitive lipase in white adipose tissue (WAT) were significantly increased 
after ZAG administration.  There was an increased expression of uncoupling proteins 
1 and 3 in brown (BAT) and white adipose tissue (WAT), which would contribute to 
increased substrate utilisation.  Administration of ZAG increased its expression in 
gastrocnemius muscle, BAT and WAT, which was probably necessary for its 
biological effect.  These results show that ZAG produces increased lipid mobilization 
and utilization in the rat. 
 
Keywords: Zinc-2-glycoprotein; lipolysis; uncoupling proteins; glucose transporter 
4; adipose triglyceride lipase; hormone sensitive lipase.  
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Introduction 
Obesity is a major problem of the twenty-first century with up to 25% of 
adults considered to be obese (21).  Our previous studies (11, 25) have identified zinc-
2-glycoprotein (ZAG), a soluble protein with sequence homology to 
histocompatibility antigens (1), as a potential treatment for obesity.  ZAG was 
originally isolated as a lipid mobilising factor (LMF) responsible for fat loss in cancer 
cachexia, and was found to be expressed by tumours that produced a decrease in 
carcass lipids (29).  Subsequent studies showed ZAG to be produced by a range of 
normal tissues including liver, heart and lung, as well as white (WAT) and brown 
(BAT) adipose tissue (5), suggesting that it was a new adipokine.  Moreover, ZAG 
expression in liver, WAT and BAT was upregulated during the phase of weight loss 
in mice bearing a cachexia-inducing tumor, with the largest increase (10-fold) being 
in WAT (5).  Both glucocorticoids and3 agonists increased expression of ZAG 
mRNA in 3T3-L1 adipocytes (5), and glucocorticoids are probably responsible for the 
increase in ZAG expression seen in adipose tissue of cachexic mice (24).   
In contrast with cachexia, adipose tissue of obese subjects shows only one-
third the expression of ZAG seen in nonobese individuals (6).  Recent studies (16) 
show that the ZAG mRNA level in visceral and subcutaneous fat of human subjects to 
be negatively correlated with BMI and fat mass, as well as parameters of insulin 
resistance.  Studies using a mouse model of obese type 2 diabetes have also identified 
ZAG as a possible candidate gene for obesity (8).  The effect of ZAG depletion has 
been studied in mice with inactivation of both ZAG alleles by gene targeting (20).  
ZAG depletion led to an increase in body weight compared with wild-type mice, 
especially when the animals were fed a high fat diet, while there was a decreased 
lipolytic activity in epididymal adipocytes in response to isoprenaline, a 3-agonist, 
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and agents which increase cyclic AMP (20).  These results suggest that loss of ZAG 
may be responsible for obesity in some individuals. 
To date all studies on the lipid mobilising effect of ZAG have been carried out 
in mice (11, 25), using human ZAG, although the identities in amino acid sequence of 
ZAG between mouse and human is only 58.6% (30).  Since the sequence homology 
between rat and mouse is 88.5% (30) this suggests that if human ZAG binds to the 
mouse receptor it should also be effective in the rat.  The current study investigates 
the anti-obesity effect of human ZAG in mature male Wistar rats. 
 
Research methods and procedures 
Materials FreeStyle media was purchased from Invitrogen (Paisely, UK).  2-[1-
14C]Deoxy-D-glucose (sp.act. 1.85GBq mmol-1) was from American Radiolabelled 
Chemicals (Cardiff, UK).  Rabbit polyclonal antibody to total p38MAPK and 
phospho PLA2 (Ser-505) were purchased from Abcam (Cambridge, UK).  Mouse 
monoclonal antibody to full length human ZAG was from Santa Cruz (California, 
USA) and mouse monoclonal antibody to myosin heavy chain type II was from 
Novocastra (via Leica Biosytems, Newcastle, UK).  Mouse monoclonal antibody to 
20S proteasome -subunits was from Affinity Research Prodcts (Exeter, UK).  Mouse 
monoclonal antibody to phospho (Thr-180/Tyr-182) p38MAPK and rabbit polyclonal 
antisera to total and phospho (Thr-451) PKR, phospho (Ser-162) eIF2 and to total 
eIF2 were from New England Biosciences (Herts, UK).  Polyclonal rabbit antibodies 
to UCP1 and UCP3 were from Calbiochem (via Merck Chemicals, Nottingham, UK).  
Peroxidase-conjugated goat anti-rabbit and rabbit anti-mouse antibodies were 
purchased from Dako (Cambridge, UK).  Polyclonal rabbit antibody to mouse β-actin 
and the triglyceride assay kit were purchased from Sigma Aldrich (Dorset, UK).  
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Hybond A nitrocellulose membranes and enhanced chemiluminescene (ECL) 
development kits were from GE Healthcare (Bucks, UK).  A WAKO colorimetric 
assay kit for measurement of NEFA was purchased from Alpha Laboratories 
(Hampshire, UK), and a mouse insulin ELISA kit was purchased from DRG 
(Marburg, Germany).  Glucose measurements were made using a plasma glucose 
assay kit (Boots, Nottingham, UK).   
 
Production of recombinant ZAG  HEK293 cells were transfected with full length 
human ZAG cDNA in the expression vector pcDNA 3.1, and maintained in FreeStyle 
medium under an atmosphere of 5% CO2 in air at 37°C.  ZAG was secreted into the 
medium, which was collected, and maximal protein levels (16gml-1) were obtained 
after 14 days of culture.  To purify ZAG, media (200ml) was centrifuged at 700g for 
15min to remove cells, and concentrated into a volume of 1ml sterile PBS using an 
Amicon Ultra-15 centrifugal filter with a 10kDa cut-off.  The concentrate (about 2mg 
protein) was added to 2g DEAE cellulose suspended in 20ml 10mM Tris, pH 8.8 and 
stirred for 2h at 4°C.  The DEAE cellulose bound ZAG and it was sedimented by 
centrifugation (1500g for 15min) and the ZAG was eluted by stirring with 20ml 
10mM Tris, pH8.8 containing 0.3M NaCl for 30min at 4°C.  The eluate was washed 
and concentrated into a volume of 1ml in sterile PBS using an Amicon centrifugal 
filter.  The purified ZAG was free of endotoxin, as determined with a LAL Pyrogent 
single test kit (Lonza, Bucks, UK) 
 
Lipolytic activity in rat adipocytes White adipocytes were prepared from finely 
minced epididymal adipose tissue of male Wistar rats (400g) using collagenase 
digestion, as described (4).  Lipolytic activity was determined by incubating 105-
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2x105 adipocytes for 2h in 1ml Krebs-Ringer bicarbonate buffer, pH7.2, and the 
extent of lipolysis was determined by measuring the glycerol released (33).  
Spontaneous glycerol release was measured by incubating adipocytes alone.  
Lipolytic activity was expressed as mol glycerol released/105 adipocytes/2h. 
 
Glucose uptake into adipocytes  Isolated adipocytes (5x104) were washed twice in 
1ml Krebs-Ringer bicarbonate buffer, pH7.2 (KRBS) and further incubated for 10min 
at room temperature in 0.5ml KRBS containing 18.5MBq 2-[1-14C] deoxy-D-glucose 
and non-radioactive 2-deoxy-D-glucose to a final concentration of 0.1mM.  Uptake 
was terminated by the addition of 1ml ice-cold glucose-free KRBS, and the cells were 
washed three times with 1ml KRBS, lysed by addition of 0.5ml 1M NaOH, and left 
for at least 1h at room temperature before the radioactivity was determined by liquid 
scintillation counting. 
 
Glucose uptake into gastrocnemius muscle  Gastrocnemius muscles were incubated in 
Krebs-Henseleit bicarbonate buffer for 45min at 37°C and then incubated for a further 
10min in 5ml Krebs-Henseleit buffer containing 185MBq 2-[1-14C] deoxy-D-glucose 
and non-radioactive 2-deoxy-D-glucose to a final concentration of 0.1mM.  the 
muscles were then removed and washed in 0.9% NaCl for 5min followed by 
dissolution in 0.5ml 1MNaOH and the radioactivity was determined by liquid 
scintillation counting. 
 
Animal studies Mature male Wistar rats (one year old from our own colony) weighing 
540±82.5g were housed individually and treated once daily i.v., with either ZAG in 
PBS (100l) (50g per 100g body weight), or with PBS (100l) as a control.  Both 
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food and water intake and body weight were measured daily.  Animals were given 
free access to food (Special Diet Services, Essex, UK) and water ad libitum.  The 
animal experiment was carried out under the welfare conditions imposed by the 
British Home Office.  After 10 days treatment the animals were terminated and the 
body composition determined.  Animals were heated to 80-90°C for 7 days until 
constant weight was achieved.  The water content was then determined from the 
difference between the wet and dry weight.  Lipids were extracted from the dry 
carcass using a sequence of chloroform:methanol (1:1), ethanol/acetone (1:1) and 
diethyl ether (120ml of each) as described by Lundholm et al (14).  The solvents were 
evaporated and the fat weighed.  The non-fat carcass mass was calculated as the 
difference between the initial weight of the carcass and the weight of water and fat. 
 
Western blotting Samples of epididymal WAT, BAT and gastrocnemius muscle 
excised from rats treated with ZAG or PBS for 5 days were homogenised in 0.25M 
sucrose, 1mM HEPES, pH 7.0 and 0.2MEDTA, and then centrifuged for 10min at 
4,500 r.pm.  Samples of cytosolic protein (10g) were resolved on 12% sodium 
dodecylsulphate polyacrylamide gel electrophoresis and the proteins were then 
transferred onto 0.45m nitrocellulose membranes, which had been blocked with 5% 
Marvel in Tris-buffered saline, pH7.5, at 4°C overnight, and following four 15 min 
washes with 0.1% Tween in PBS, incubation with the secondary antibody was 
performed for 1h at room temperature.  Development was by ECL. 
 
Statistical analysis Results were expressed as mean ± s.e.m.  Differences were 
determined by one-way ANOVA, followed by Tukey-Kramer multiple comparison 
test.  P-values less than 0.05 were considered significant. 
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Results 
The lipolytic effect of human ZAG towards rat epididymal adipocytes in 
comparison with isoprenaline is shown in Figure 1.  At concentrations between 233 
and 700nM ZAG produced a dose-related increase in glycerol release, which was 
attenuated by anti-ZAG monoclonal antibody showing the specificity of the action.  
The extent of lipolysis in rat adipocytes was similar to that previously reported in the 
mouse (25).  As in the mouse the lipolytic effect of ZAG was completely attenuated 
by the 3-adrenergic receptor (3-AR) antagonist SR59230A (17), suggesting that the 
action of ZAG was mediated through 3-AR.  These results suggest that ZAG may be 
effective in inducing fat loss in rats. 
The effect of single daily i.v. injection of ZAG (50g/100g b.w.) on the body 
weight of mature male Wistar rats (540±83g) is shown in Figure 2A.  Compared with 
control rats administered the same volume of solvent (PBS), rats administered ZAG 
showed a progressive decrease in body weight, such that after 10 days, while rats 
treated with PBS showed a 13g increase in body weight, animals treated with ZAG 
showed a 5g decrease in body weight (Table 1).  There was no difference in food 
(ZAG: 102±32g; PBS:98±25g) or water (ZAG: 135±35ml; PBS: 125±25ml) intake 
between the two groups during the course of the study, but ZAG-treated animals 
showed a consistent 0.4°C elevation in body temperature, which was significant 
within 24h of the first administration of ZAG (Figure 2B), indicating an elevated 
energy expenditure.  Body composition analysis (Table 1) showed that the loss of 
body weight induced by ZAG was due to a loss of carcass fat, which was partially 
offset by a significant increase in lean body mass.  There was a 50% increase in 
plasma glycerol concentration in rats treated with ZAG (Table 2), indicative of an 
increased lipolysis, but a 55% decrease in plasma levels of non-esterified fatty acids 
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(NEFA), suggesting an increased utilisation.  Plasma levels of glucose and 
triglycerides were also reduced by 36-37% (Table 2), also suggesting an increased 
utilisation.  Plasma levels of insulin fell in proportion to the decrease in blood glucose 
levels.  There was a significant increase in the uptake of 2-deoxygluocse into 
epididymal adipocytes of rats treated with ZAG for 10days, which was increased in 
the presence of insulin (Figure 2C).  However, there was no significant difference in 
glucose uptake into adipocytes from ZAG or PBS treated animals in the presence of 
insulin (Figure 2C).  There was a small, non-significant increase in glucose uptake 
into gastrocnemius muscle and BAT of rats treated with ZAG in comparison with 
PBS controls, but a significant increase in uptake in the presence of insulin (Figure 
2D).  These results suggest that the decrease in blood glucose is due to increased 
utilisation by BAT, WAT and skeletal muscle, and this is supported by an increased 
expression of glucose transporter 4 (GLUT4) in all three tissues (Figure 3). 
ZAG administration increased expression of the uncoupling proteins (UCP)-1 
and -3 in both BAT and WAT (Figure 3A and 3B), which would contribute to 
increased substrate utilisation.  In rats treated with ZAG there was also an increased 
expression of the lipolytic enzymes adipose triglyceride lipase (ATGL) and hormone 
sensitive lipase (HSL) in epididymal adipose tissue (Figure 5).  ATGL is mainly 
responsible for the hydrolysis of the first ester bond in a triacylglycerol molecule 
forming diacylgylcerol, while its conversion to monacylglycerol is carried out by 
HSL.  Expression of ZAG was also significantly increased in skeletal muscle, (Figure 
6A), WAT (Figure 6B) and BAT (Figure 6C) of rats treated with ZAG for 10 days, 
showing that exogenous ZAG boosts its own production in peripheral tissues. 
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Discussion 
ZAG has been attributed a number of biological roles (10), but its role as an 
adipokine regulating lipid mobilisation and utilisation is most important in regulating 
body composition.  Our previous studies (11) identified ZAG as a lipid mobilising 
factor capable of inducing lipolysis in white adipocytes of the mouse in a GTP-
dependent process, similar to that induced by lipolytic hormones.  This study shows 
that ZAG has a similar lipolytic effect in rat adipocytes, and, moreover, produces a 
decrease in body weight and carcass fat in mature male rats, despite the fact that the 
sequence homology between rat and human ZAG is only 59.4% (30). 
The results of this study show that ZAG administration to the rat also 
increases the expression of ATGL and HSL in the rat.  ATGL may be important in 
excess fat storage in obesity, since ATGL knockout mice have large fat deposits and 
reduced free fatty acids release from WAT in response to isoproterenol although they 
did display normal insulin sensitivity (9).  In contrast HSL null mice, when fed a 
normal diet, had body weights similar to wild-type animals (18).  However, 
expression of both ATGL and HSL are reduced in human WAT in the obese insulin-
resistant state compared with the insulin sensitive state, and weight reduction also 
decreased mRNA and protein levels (13). 
Stimulation of lipolysis alone would not deplete body fat stores, since without 
an energy sink the liberated NEFA would be resynthesised back into triglycerides in 
adipocytes (9).  To reduce body fat ZAG not only increases lipolysis, as shown by an 
increase in plasma glycerol, but also increases lipid utilisation, as shown by the 
decrease in plasma levels of triglycerides and NEFA.  This energy is channelled into 
heat, as evidenced by the 0.4°C rise in body temperature in rats treated with ZAG.  
The increased energy utilisation most likely arises from the increased expression of 
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UCP1, which has been shown in both BAT and WAT after administration of ZAG.  
An increased expression of UCP1 would be expected to decrease plasma levels of 
NEFA, since they are the primary substrates for thermogenesis in BAT (28).  BAT 
also has a high capacity for glucose utilisation (15), which could partially explain the 
decrease in blood glucose.  In addition there was increased expression of GLUT4 in 
skeletal muscle and WAT, which helps mediate the increase in glucose uptake in the 
presence of insulin (27).  In mice treated with ZAG there was an increased glucose 
utilisation by brain, heart, BAT and gastrocnemius muscle, and increased production 
of 14CO2 from D-[U-14C] glucose, as well as [14C carboxy] triolein (23).  There was 
also a three-fold increase in oxygen uptake by BAT of ob/ob mice after ZAG 
administration (11). 
Induction of lipolysis in rat adipocytes by ZAG is suggested to be mediated 
through a β3-AR, and the effect of ZAG on adipose tissue and lean body mass may 
also be due to its ability to stimulate the β3-AR (22).  Induction of UCP1 expression 
by ZAG has been shown to be mediated through interaction with a β3-AR (26).  The 
increased expression of UCP1 in WAT may also be a β3-AR effect through 
remodelling of brown adipocyte precursors, as occurs with the β3-AR agonist 
CL316,243 (7).  Using knock-out mice the antiobesity effect of β3-AR stimulation 
has been mainly attributed to UCP1 in BAT, and less to UCP2 and UCP3 through the 
UCP1-dependent degradation of NEFA released from WAT (12).  Glucose uptake 
into peripheral tissues of animals is stimulated by cold-exposure, an effect also 
mediated through the β3-AR (31).  However, targeting the β3-AR has been more 
difficult in humans than in rodents, since β3-AR play a less prominent role than β1 
and β2-AR subtypes in the control of lipolysis and nutritive blood flow in human 
subcutaneous abdominal adipose tissue (2).  However, despite this the β3-AR agonist 
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CL316,243 has been shown to increase fat oxidation in healthy young male volunteers 
(32).  This may be due to the ability of β-adrenergic agonists to increase the number 
of β3-AR in plasma membranes from BAT (32). 
Recent results (16) suggest that ZAG expression in adipose tissue may be 
more important locally than circulating ZAG, by acting in a paracrine manner.  Thus 
in humans, while mRNA levels of ZAG in visceral and subcutaneous fat correlated 
negatively with BMI, fat mass and insulin resistance (16), serum levels, determined 
by ELISA, correlated positively with parameters of adiposity (BMI and waist 
circumference) and insulin resistance (31).  Thus the ability of ZAG to induce its own 
expression in gastrocnemius muscle, WAT and BAT may be critical for its ability to 
increase lipolysis and energy utilisation. 
These results provide evidence for the ability of ZAG to mobilise and utilise 
lipid in rats, confirming a species independent effect, and suggest that it may be useful 
as an antiobesity agent in man. 
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Figure Legends 
 
Figure 1 Lipolytic activity of human ZAG in isolated rat epididymal adipocytes, 
compared with isoprenaline (10M) in the absence or presence of SR59230A 
(10M) or anti-ZAG antibody (1:1000) (IgG).  Each value is an average of 5 
separate studies.  Differences from control are shown as b, p<0.01 or c, 
p<0.001, while differences from ZAG alone are indicated as e, p<0.01 or f, 
p<0.001. 
Figure 2 (A) Effect of daily i.v. administration of either ZAG (50g/100g b.w.) in 
100l PBS () or PBS alone () on body weight of male Wistar rats over a 
10 day period.  The protocol for the experiment is given in the methods 
section.  (B) Body temperature of male Wistar rats administered either ZAG 
() or PBS () as described in (A).  (C) Uptake of 2-deoxy-D-glucose into 
epididymal adipocytes of male Wistar rats after 10 days treatment with either 
ZAG or PBS for 10 days, as shown in (A), in the absence (closed box) or 
presence (open box) of insulin (60U/ml).  (D) Glucose uptake into 
gastrocnemius muscle and BAT of male Wistar rats after 10 days treatment 
with either ZAG (closed box) or PBS (open box), in the absence or presence 
of insulin (60U/ml).  Differences between ZAG and PBS treated animals are 
shown as b, p<0.01 or c, p<0.001, while differences in the presence of insulin 
are shown as d, p<0.05 or f, p<0.001. 
Figure 3 Western blots showing expression of GLUT4 in BAT (A) and WAT (B) and 
gastrocnemius muscle (C) of male Wistar rats treated with either PBS or ZAG 
for 10 days as shown in Figure 2. 
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Figure 4 Western blots showing expression of UCP1 and UCP3 in BAT (A) and WAT 
(B) of male Wistar rats treated with either PBS or ZAG for 10 days as shown 
in Figure 2. 
Figure 5 Expression of ATGL (A) and HSL (B), detected by Western blotting, in 
epididymal adipose tissue of male Wistar rats treated with either PBS or ZAG 
for 10 days as shown in Figure 2. 
Figure 6 Expression of ZAG in gastrocnemius muscle (A), WAT (B) and BAT (C), 
detected by Western blotting of tissues excised from male Wistar rats treated 
with either PBS or ZAG for 10 days as shown in Figure 2. 
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Table 1 Body composition of male rats after treatment with either PBS or ZAG 
Treatment Starting weight  
(g) 
Final weight  
(g) 
Weight change  
(g) 
Water  
(g)              (%) 
Fat  
(g)            (%) 
Non fat  
(g)              (%) 
PBS 510±30 523±2 +13±3 326±32        62±2 105±14    20±3 90±6           17±3 
ZAG 530±45 525±1 -5±1 331±5         63±3 92±5b       18±1 96±2a          18±2 
 
Differences from animals treated with PBS are shown as a, p<0.05 or b, p<0.01 
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Table 2 Plasma metabolite and insulin levels in rats treated with either PBS or ZAG for 10 days 
 
 
 PBS ZAG 
Glucose mmol/l 25.5±2.3 16.2±2.1c 
Trigylcerides mmol/l 1.75±0.01 1.1±0.09a 
Glycerol umol/l 300±52 450±51c 
NEFA mEq/l 0.58±0.008 0.26±0.06b
 
 
Differences from animals treated with PBs are shown as either a, p<0.05; b, p<0.01 or c, p<0.001 
